(powerpoint)
TRANSCRIPT
![Page 1: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/1.jpg)
Eculizumab in aHUS
Elaine Majerus, MD PhD
February 21, 2009
![Page 2: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/2.jpg)
Disclosures
• Uncompensated consultant for Alexion in the development of this trial.
![Page 3: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/3.jpg)
Case Presentation
• 28 y/o WF w/ a h/o migraines, anxiety, and lower back pain who presented 1/8/09 to OSH ER with complaints of nausea, vomiting, and abdominal pain for 1 week. Was in usual state of health until Thanksgiving when she developed URI symptoms. PMD gave Biaxcin. Symptoms resolved but then developed
![Page 4: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/4.jpg)
Case cont.
• Sore throat and ear pain. Given Aleve by her physician. Re-presented to PMD one prior to admission with N/V and abd pain and was send to ED with abnormal UA.
• Meds: Lexapro 20 QD, OCP, Colace prn.• All: PCN; Cleocin, rash.• PMHx: C-sxn• FHx: F with HTN, GF with DM• SHx: works as an OT. Married with 3 y/o
daughter. Denies A/T/D.
![Page 5: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/5.jpg)
Case cont.
PE: T=37.3 P=78 BP=176/90
WD/WN WF anxious, NAD.
Skin: petechiae on face and chest.
Lungs: CTA CV: RRR
Abd: soft, mild RLQ tenderness, +BS
Ext: edema in UE and LE
![Page 6: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/6.jpg)
Labs
• OSH: Hb 9.1/78 Plt 96 WBC 13.4• BUN101; Cr8; K4.5.• UA with 5-10 granulocytic casts, 3+
protein, 3+ blood.• Renal US with increased echogenicity
c/w chronic renal disease.• ANA -; ASO titer -; anti-GBM -.• 24 hour urine protein 5.3.
![Page 7: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/7.jpg)
Labs cont.
• 1/11. WBC 7.3 Hb 5.6 Plt 67 LDH 1500; Hapto undetectable. 1-2 schistocytes per HPF.
![Page 8: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/8.jpg)
Diagnosis
• Started on plasma exchange for ? Of thrombotic microangiopathy.
• ADAMTS13 sent and Nl.• Plt bounced around to as low as 40,000.• Receive packed RBCs.• No response to plasma exchange after 10
days.• Dialyzed for volume overload and remained
on HD.
![Page 9: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/9.jpg)
Atypical Hemolytic Uremic Syndrome (aHUS)
• Non-diarrheal, not Shiga toxin related.• Sporadic or familial.• Warwicker et al. in 1998 identified an
association in three families with aHUS with the Regulators of Complement Activation gene cluster on 1q32.
• Genes for Factor H, MCP, and DAF are located there.
![Page 10: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/10.jpg)
Mutations have been found in five complement factors:
![Page 11: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/11.jpg)
• Mutations in Factor B and C3 have also been identified.
• Inhibitory antibodies directed against Factor H have also been found associated with atypical HUS
![Page 12: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/12.jpg)
Diagnosis with HUS
• Genetic screening identifies mutations but is expensive (and slow with sendout).
• Assessment of protein levels can be helpful using antigenic assays or flow cytometry.
• Normal C3 levels do not rule out a mutation.• C3, C4, and factor B levels are usually
normal.
![Page 13: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/13.jpg)
![Page 14: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/14.jpg)
![Page 15: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/15.jpg)
![Page 16: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/16.jpg)
Inactivation
+ Factor I
Binding
MCP MCP
C3bC3b iC3b C3f
Inactivation
+ Factor I
Binding
MCPC4d
MCP
C4b C4cC4b
Cofactor ActivityCofactor Activity
Factor H Factor H
Factor I
I + + I
![Page 17: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/17.jpg)
Complement regulators in aHUSComplement regulators in aHUSProtein Synthesized Function
(C3b)Mutation
(%)
FHFH LiverLiver CofactorCofactor 20 to 3020 to 30
MCP MCP (CD46)(CD46)
CellsCells CofactorCofactor 10 to 2010 to 20
FIFI LiverLiver ProteaseProtease 5 to 155 to 15
![Page 18: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/18.jpg)
Factor H mutationsFactor H mutations
19 20
1 - 4
Cofactor Site
![Page 19: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/19.jpg)
s s
922delC*
R317W
(1446-1450) del5bp
W486X*
W546X*
D519N
D524V
C1610ins AT*
IVS12+5G>T
A240GM138I
W145X*
Fact
or I
mod
ule
CD5 do
mai
n
LDLr
mod
ule
LDLr
mod
ule
Serin
e pr
otea
se d
omai
n
G271D
Factor I MutationsFactor I Mutations
in aHUSin aHUS
![Page 20: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/20.jpg)
MCP mutations in aHUS MCP mutations in aHUS
![Page 21: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/21.jpg)
Factor B
• A family was recently identified with gain of function mutations in Factor B.
• Leads to enhanced formation of the C3bBb convertase.
• Increased resistance to inactivation by complement regulators.
![Page 22: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/22.jpg)
Inheritance
• Heterozygous expression leads to disease.
• Homozygotes are also seen with MCP mutations.
• Presentation usually occurs by 30 years of age. Most present in childhood.
![Page 23: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/23.jpg)
• Penetrance is about 50%. Most “sporadic cases” have an unaffected parent with the disease-causing mutation.
• Other genetic or environmental factors involved.
• Disease is recurrent and leads to loss of renal function.
![Page 24: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/24.jpg)
Treatment
• Plasma exchange.
• No prospective randomized controlled trials.
• Overall mortality decreased from 50% to 25% with the introduction of plasma infusion or exchange.
![Page 25: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/25.jpg)
Renal Transplantation
• Transplant in those with MCP mutations has been successful since it is a membrane protein.
• Those with Factor H mutations should not be transplanted since Factor H is made in the liver and the kidney is still susceptible to damage. (80% chance of recurrence.)
• Factor I mutations are thought to have a similar risk of recurrence.
![Page 26: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/26.jpg)
• Potential donors who are family members should be screened for the MCP mutation since the penetrance is incomplete.
![Page 27: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/27.jpg)
aHUS Conclusions
• Inciting event such as bacterial or viral infection or pregnancy.
• Robust complement activity leads to endothelial and renal damage.
• Fibrin-rich thrombi develop.
![Page 28: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/28.jpg)
• If aHUS is an activated complement syndrome, could decreasing complement activity help?
• Eculizumab is an antibody directed against C5 of the terminal complement cascade.
• Effective for PNH.
![Page 29: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/29.jpg)
Investigator-initiated Trial
• Submitted to Alexion in 2/08 using eculizumab for aHUS and following platelet, Haptoglobin, and LDH for response.
• With low patient numbers, a company-sponsored international trial was best option.
• Abstracts at ASH 12/08.
![Page 30: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/30.jpg)
Poster Session
Disorders of Platelet Number or Function Poster II
Successful Treatment of Atypical Hemolytic Uremic Syndrome with the Complement Inhibitor Eculizumab.
Jens Nuernberger1,*, Oliver Witzke1,*, Russell P. Rother, PhD2,*, Thomas Philipp1,*, Udo Vester1,*, Hideo Baba1,*, Lothar Bernd Zimmerhackl3,* and Andreas Kribben1,*
1 Department of Nephrology, University Duisburg-Essen, Essen, Germany, 2 Research, Alexion Pharmaceuticals, Cheshire, CT, USA, 3 Department of Pediatrics, Innsbruck Medical University, Innsbruck, Austria
![Page 31: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/31.jpg)
![Page 32: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/32.jpg)
Disorders of Red Cell Regulation and Production
Efficacy of Eculizumab in a Plasmatherapy-Dependent Patient with Atypical Hemolytic Uremic Syndrome with C3 Mutation Following Plasmatherapy Withdrawal
Valerie Chatelet, MD1,*, Veronique Fremeaux-Bacchi, MD, PhD2,*,Maxence Ficheux, MD1,*, Thierry Lobbedez, MD1,* and Bruno Hurault-Deligny, MD1,*
1 Nephrology Department, CHU Clemenceau, Caen, France,2 Immunology Department, HEGP, Paris, France
![Page 33: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/33.jpg)
Blood (ASH Annual Meeting Abstracts) 2008 112: Abstract 2294© 2008 American Society of Hematology
![Page 34: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/34.jpg)
ADAMTS13 <5% Cr, microM 119 +/- 14 SEM
ADAMTS13 >5% 206 +/- 58
P=0.042
![Page 35: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/35.jpg)
![Page 36: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/36.jpg)
![Page 37: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/37.jpg)
Conclusions
• Great job of screening and recognizing these patient.
• If idiopathic thrombotic microangiopathy and nl ADAMTS13, think aHUS.
• Inclusion criteria will be basically this.
![Page 38: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/38.jpg)
Thank You
• Luke
• Jeevan
• John Atkinson
![Page 39: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/39.jpg)
![Page 40: (PowerPoint)](https://reader035.vdocuments.mx/reader035/viewer/2022062419/557a9111d8b42ac8638b522b/html5/thumbnails/40.jpg)